Cerenia

RSS

maropitant

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 09/11/2018

Authorisation details

Product details
Name
Cerenia
Agency product number
EMEA/V/C/000106
Active substance
maropitant citrate
International non-proprietary name (INN) or common name
maropitant
Species
  • Dogs
  • Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QA04AD90
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
19
Date of issue of marketing authorisation valid throughout the European Union
28/09/2006
Contact address
Rue Laid Burnait, 1
1348 Louvain-la-Neuve
Belgium

Product information

31/10/2018 Cerenia - EMEA/V/C/000106 - IB/0035/G

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Alimentary track and metabolism
  • Other antiemetics

Therapeutic indication

Tablets

Dogs:

  • For the prevention of nausea induced by chemotherapy.
  • For the prevention of vomiting induced by motion sickness.
  • For the prevention and treatment of vomiting, in conjunction with Cerenia solution for injection and in combination with other supportive measures.

Solution for injection

Dogs:

  • For the treatment and prevention of nausea induced by chemotherapy.
  • For the prevention of vomiting except that induced by motion sickness.
  • For the treatment of vomiting, in combination with other supportive measures.
  • For the prevention of perioperative nausea and vomiting and improvement in recovery from general anaesthesia after use of the μ-opiate receptor agonist morphine.

Cats:

  • For the prevention of vomiting and the reduction of nausea, except that induced by motion sickness.
  • For the treatment of vomiting, in combination with other supportive measures.

Assessment history

How useful was this page?

Add your rating